Cargando…

Complete Response to Combined Chemotherapy and Anti-PD-1 Therapy for Recurrent Gallbladder Carcinosarcoma: A Case Report and Literature Review

BACKGROUND: Gallbladder carcinosarcoma (GBCS) is a rare and aggressive malignancy with extremely poor prognosis. Although surgery is regarded as the primary therapy for GBCS, the effective therapeutic strategies for unresected lesions have been poorly defined. CASE PRESENTATION: We presented a case...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qin-qin, Lin, Hao-ming, Han, Hong-wei, Yang, Cai-ni, Liu, Chao, Zhang, Rui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967174/
https://www.ncbi.nlm.nih.gov/pubmed/35372010
http://dx.doi.org/10.3389/fonc.2022.803454
_version_ 1784678784472973312
author Liu, Qin-qin
Lin, Hao-ming
Han, Hong-wei
Yang, Cai-ni
Liu, Chao
Zhang, Rui
author_facet Liu, Qin-qin
Lin, Hao-ming
Han, Hong-wei
Yang, Cai-ni
Liu, Chao
Zhang, Rui
author_sort Liu, Qin-qin
collection PubMed
description BACKGROUND: Gallbladder carcinosarcoma (GBCS) is a rare and aggressive malignancy with extremely poor prognosis. Although surgery is regarded as the primary therapy for GBCS, the effective therapeutic strategies for unresected lesions have been poorly defined. CASE PRESENTATION: We presented a case of a 74-year-old male who underwent radical resection of gallbladder carcinoma at a local hospital. Seven months later, he was admitted to our hospital due to right upper abdominal discomfort. Postoperative radiological examinations showed multiple hepatic lesions, hilar lymph node metastasis, and main portal vein tumor thrombus. The pathological consultation results confirmed GBCS and immunohistochemical examinations revealed PD-L1 expression in 20% of tumor cells. Then, the patient received chemotherapy (Gemcitabine plus Oxaliplatin, GEMOX) in combination with anti-PD-1 therapy. After nine courses of the combination therapy, complete regression of the tumors was achieved with no evidence of relapse till now. CONCLUSIONS: We, for the first time, reported a patient with recurrent GBCS who benefited from the combined chemotherapy and immunotherapy, providing a potential effective management strategy for the refractory malignant tumor.
format Online
Article
Text
id pubmed-8967174
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89671742022-03-31 Complete Response to Combined Chemotherapy and Anti-PD-1 Therapy for Recurrent Gallbladder Carcinosarcoma: A Case Report and Literature Review Liu, Qin-qin Lin, Hao-ming Han, Hong-wei Yang, Cai-ni Liu, Chao Zhang, Rui Front Oncol Oncology BACKGROUND: Gallbladder carcinosarcoma (GBCS) is a rare and aggressive malignancy with extremely poor prognosis. Although surgery is regarded as the primary therapy for GBCS, the effective therapeutic strategies for unresected lesions have been poorly defined. CASE PRESENTATION: We presented a case of a 74-year-old male who underwent radical resection of gallbladder carcinoma at a local hospital. Seven months later, he was admitted to our hospital due to right upper abdominal discomfort. Postoperative radiological examinations showed multiple hepatic lesions, hilar lymph node metastasis, and main portal vein tumor thrombus. The pathological consultation results confirmed GBCS and immunohistochemical examinations revealed PD-L1 expression in 20% of tumor cells. Then, the patient received chemotherapy (Gemcitabine plus Oxaliplatin, GEMOX) in combination with anti-PD-1 therapy. After nine courses of the combination therapy, complete regression of the tumors was achieved with no evidence of relapse till now. CONCLUSIONS: We, for the first time, reported a patient with recurrent GBCS who benefited from the combined chemotherapy and immunotherapy, providing a potential effective management strategy for the refractory malignant tumor. Frontiers Media S.A. 2022-03-14 /pmc/articles/PMC8967174/ /pubmed/35372010 http://dx.doi.org/10.3389/fonc.2022.803454 Text en Copyright © 2022 Liu, Lin, Han, Yang, Liu and Zhang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Liu, Qin-qin
Lin, Hao-ming
Han, Hong-wei
Yang, Cai-ni
Liu, Chao
Zhang, Rui
Complete Response to Combined Chemotherapy and Anti-PD-1 Therapy for Recurrent Gallbladder Carcinosarcoma: A Case Report and Literature Review
title Complete Response to Combined Chemotherapy and Anti-PD-1 Therapy for Recurrent Gallbladder Carcinosarcoma: A Case Report and Literature Review
title_full Complete Response to Combined Chemotherapy and Anti-PD-1 Therapy for Recurrent Gallbladder Carcinosarcoma: A Case Report and Literature Review
title_fullStr Complete Response to Combined Chemotherapy and Anti-PD-1 Therapy for Recurrent Gallbladder Carcinosarcoma: A Case Report and Literature Review
title_full_unstemmed Complete Response to Combined Chemotherapy and Anti-PD-1 Therapy for Recurrent Gallbladder Carcinosarcoma: A Case Report and Literature Review
title_short Complete Response to Combined Chemotherapy and Anti-PD-1 Therapy for Recurrent Gallbladder Carcinosarcoma: A Case Report and Literature Review
title_sort complete response to combined chemotherapy and anti-pd-1 therapy for recurrent gallbladder carcinosarcoma: a case report and literature review
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8967174/
https://www.ncbi.nlm.nih.gov/pubmed/35372010
http://dx.doi.org/10.3389/fonc.2022.803454
work_keys_str_mv AT liuqinqin completeresponsetocombinedchemotherapyandantipd1therapyforrecurrentgallbladdercarcinosarcomaacasereportandliteraturereview
AT linhaoming completeresponsetocombinedchemotherapyandantipd1therapyforrecurrentgallbladdercarcinosarcomaacasereportandliteraturereview
AT hanhongwei completeresponsetocombinedchemotherapyandantipd1therapyforrecurrentgallbladdercarcinosarcomaacasereportandliteraturereview
AT yangcaini completeresponsetocombinedchemotherapyandantipd1therapyforrecurrentgallbladdercarcinosarcomaacasereportandliteraturereview
AT liuchao completeresponsetocombinedchemotherapyandantipd1therapyforrecurrentgallbladdercarcinosarcomaacasereportandliteraturereview
AT zhangrui completeresponsetocombinedchemotherapyandantipd1therapyforrecurrentgallbladdercarcinosarcomaacasereportandliteraturereview